Atea Pharmaceuticals announced the presentation of two posters supporting the combination of bemnifosbuvir, an oral nucleotide polymerase inhibitor, and ruzasvir, an oral NS5A inhibitor, as a potential treatment for Hepatitis C Virus at the American Association for the Study of Liver Diseases’ The Liver Meeting 2023, November 10-14 in Boston. “Results from these two presented studies further support the potential use of these two drug candidates in combination as a novel treatment for HCV. Phase 1 data demonstrate that coadministration of bemnifosbuvir and ruzasvir was well tolerated and not affected by food or concomitant dosing, indicating a low risk of drug-drug interactions,” said CEO Jean-Pierre Sommadossi. “Moreover, in vitro data demonstrate that the combination of bemnifosbuvir and ruzasvir retained potent pan-genotypic antiviral activity against major HCV NS5A and NS5B resistance-associated variants and hard-to-treat sub-genotypes, which have been identified in certain HCV patients who have failed treatment with currently available therapies. We are very pleased with the substantial progress achieved in our Phase 2 combination study of bemnifosbuvir and ruzasvir for the treatment of HCV this year, and we expect to announce results from the 60-person lead-in cohort in early 2024…”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVIR:
- Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
- Atea Pharmaceuticals reports Q3 EPS (40c), consensus (48c)
- Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
- Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
- Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023